When Will NeuroBo Pharmaceuticals Inc. (NRBO) Be Worth Investing In?
NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) has a beta value of 0.63 and has seen 7.4 million shares traded in the last trading session. The company, currently valued at $89.56M, closed the last trade at $3.94 per share which meant it gained $0.83 on the day or 26.69% during that session. The NRBO stock price is -168.27% off its 52-week high price of $10.57 and 30.96% above the 52-week low of $2.72. If we look at the companys 10-day average daily trading volume, we find that it stood at 0.17 million shares traded. The 3-month trading volume is 121.07K shares. The consensus among analysts is that NeuroBo Pharmaceuticals Inc. (NRBO) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.15. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) trade information  Sporting 26.69% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 06/14/21 when the NRBO stock price touched $3.94 or saw a rise of 40.03%. Year-to-date, NeuroBo Pharmaceuticals Inc. shares have moved -24.95%, while the 5-day performance has seen it change 25.48%. Over the past 30 days, the shares of NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) have changed 42.24%. Short interest in the company has seen 0.4 million shares shorted with days to cover at 5.74. Wall Street analysts have a consensus price target for the stock at $16.00, which means that the shares value could jump 75.38% from current levels. The projected low price target is $16.00 while the price target rests at a high of $16.00. In that case, then, we find that the current price level is -306.09% off the targeted high while a plunge would see the stock gain -306.09% from current levels. NeuroBo Pharmaceuticals Inc. (NRBO) estimates and forecasts  Figures show that NeuroBo Pharmaceuticals Inc. shares have outperformed across the wider relevant industry. The companys shares have lost -28.88% over the past 6 months, with this year growth rate of 15.79%, compared to 8.70% for the industry. If we evaluate the companys growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 45.70% over the past 5 years. NRBO Dividends  NeuroBo Pharmaceuticals Inc. is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the companys debt issue. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Add them to your watchlist before they take off! Get the Top 5 Stocks Now! Sponsored  NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO)s Major holders  Insiders own 14.07% of the company shares, while shares held by institutions stand at 39.84% with a share float percentage of 46.37%. Investors are also buoyed by the number of investors in a company, with NeuroBo Pharmaceuticals Inc. having a total of 50 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 0.68 million shares worth more than $3.01 million. As of Mar 30, 2021, Vanguard Group, Inc. (The) held 3.09% of shares outstanding. The other major institutional holder is Blackrock Inc., with the holding of over 0.23 million shares as of Mar 30, 2021. The firms total holdings are worth over $0.99 million and represent 1.02% of shares outstanding. Also the top two Mutual Funds that are holding companys shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Mar 30, 2021, the former fund manager holds about 2.73% shares in the company for having 0.6 million shares of worth $2.66 million while later fund manager owns 85749.0 shares of worth $0.38 million as of Mar 30, 2021, which makes it owner of about 0.39% of companys outstanding stock.